3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Gastrointestinal
1
Conditions
Multiple Myeloma
46
Recurrence
6
Leukemia, Myeloid, Acute
5
Waldenstrom Macroglobulinemia
2
Smoldering Multiple Myeloma
2
Plasmacytoma
2
Lymphoma, Large B-Cell, Diffuse
2
Immunoglobulin Light-chain Amyloidosis
2
Carcinoma, Non-Small-Cell Lung
2
Various Advanced Cancer
1
Triple Negative Breast Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Paraproteinemias
1
Pancreatic Neoplasms
1
Neoplasms, Plasma Cell
1
Neoplasms
1
Neoplasm, Residual
1
Myelodysplastic Syndromes
1
Microsatellite Unstable Colorectal Cancer
1
Lymphoma, T-Cell
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Follicular
1
Lymphoma
1
Leukemia, Myeloid
1
Leukemia, Monocytic, Acute
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hypergammaglobulinemia
1
Hodgkin Disease
1
Amyloidosis
1
Interventions
relatlimab
1
daratumumab
1
cobimetinib
1
Nivolumab
1
Ipilimumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Microsatellite Unstable Colorectal Cancer
×
daratumumab
×
Clear all
NCT02060188
2025-11-06
CheckMate142
Bristol-Myers Squibb
Phase 2
Completed
385 enrolled
17 charts
2 FDA